Teva Pharmaceutical makes $10 million equity investment in OncoGenex Pharmaceuticals

Posted on: Fri, 25 Dec 2009 13:37:00 EST

Symbols: TEVA

Dec 25, 2009 (Datamonitor Financial Deals Tracker via COMTEX) --
TEVA | Quote | Chart | News | PowerRating -- Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, has made a $10 million equity investment in OncoGenex Pharmaceuticals, Inc., a US-based biopharmaceutical company, at a price of $37.38 per share.

Deal Value (US$ Million) 10
Deal Type                Private Placement
Sub-Category             None
Deal Status              Completed: 2009-12-21

Deal Participants

Target (Company)   OncoGenex Pharmaceuticals, Inc. (formerly Sonus Pharmaceuticals, Inc.)
Acquirer (Company) Teva Pharmaceutical Industries, Ltd.

Offer Price ($ per share) 37.38

For full details on Teva Pharm Ind (TEVA) TEVA. Teva Pharm Ind (TEVA) has Short Term PowerRatings at TradingMarkets. Details on Teva Pharm Ind (TEVA) Short Term PowerRatings is available at This Link.

How to Successfully Trade ETFs

Do you want to learn how to trade more successfully, more consistently... and with more confidence?

If so, then the TPS strategy is for you.

Hundreds, if not now thousands, of ETF traders successfully use the TPS trading strategy to find the best ETF trade set-ups each day to place winning trades.

What stocks and ETFs are headed up and down this week?.

The TradingMarkets Weekly Newsletter covers this in depth and gives performance information on the previous week.

UPCOMING EVENTS

Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.

Thursday August 19 12:30 PM

Hear What Kevin Haggerty Sees in the Stock Market Today!

Wednesday August 4 04:30 PM

Building High Performing Portfolios with The Machine

* Attendance is strictly limited and are filled on a first-come, first-served basis.

1.	The 9 Characteristics of Great Traders
2.	Controlling Risk in Short-Term Trading, Part 1
3.	Controlling Risk in Short-Term Trading: Part 2, Reducing DrawDown
4.	6 Common Traits of Successful Traders and Investors
5.	Riding the VIX
6.	9 Steps to Avoid Overtrading the Choppy Markets
7.	How Intraday Volume Can Be Used by Day Traders
8.	5 Uncommon Rules of Wealthy Traders
9.	10 Steps to Successful Day Trading, Part 2
10.	How to Maintain Your Trading Confidence

Name	Symbol	PR
PowerShares DB US Dollar Bullish Fund	UUP	10
iPath S&P 500 VIX Mid-Term Futures ETN	VXZ	10
ProShares UltraShort MSCI Brazil	BZQ	9
PowerShares DB Gold Double Long Exchange Traded Note	DGP	9
Direxion Developed Markets Bear 3X Shares	DPK	9
ProShares UltraShort MSCI EAFE	EFU	9
ProShares Trust II: UltraShort Euro	EUO	9
SPDR Gold Shares	GLD	9
iShares COMEX Gold Trust	IAU	9
Powerwave Technologies	PWAV	9

About TradingMarkets Advertise Contact Careers Link to Us Help Terms & Conditions Privacy Policy Return Policy Testimonials Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.